

NF-κB SN50 cell permeable inhibitory peptide

Inhibits NF-κB translocation

Sequence contains the nuclear localization sequence (NLS residues 360-369) of the transcription factor NF-κB p50 linked to a peptide cell-permeabilization sequence, the hydrophobic region (h-region) of the signal peptide of Kaposi fibroblast growth factor (K-FGF). Peptide inhibits translocation of the NF-κB active complex into the nucleus. In mouse endothelial LE-II cells induced with LPS, inhibition of NF-κB nuclear translocation was 88% at 50μg/ml (18 μM). In human monocytic THP-1 cells induced by LPS or TNFα there was 85% inhibition at 100μg/ml. Sold under license from Vanderbilt University.

Citations: 14

[View Online »](#)

Ordering Information

[Order Online »](#)

BML-P600-0005	0.5mg
---------------	-------

Manuals, SDS & CofA

[View Online »](#)

Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended.

Long Term Storage -20°C

Shipping Blue Ice

Regulatory Status RUO - Research Use Only

Product Details

Appearance Lyophilized solid.

CAS 213546-53-3

MW 2781.5

Purity ≥97% (HPLC)

Sequence Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro

Solubility Soluble in water, 100% ethanol or 50% ethanol.



ENZO LIFE SCIENCES,
INC.
Phone: 800.942.0430
[info-
usa@enzolifesciences.com](mailto:info-usa@enzolifesciences.com)

European Sales Office
ENZO LIFE SCIENCES
(ELS) AG
Phone: +41 61 926 8989
[info-
eu@enzolifesciences.com](mailto:info-eu@enzolifesciences.com)

Belgium, The Netherlands
& Luxembourg
Phone: +32 3 466 0420
[info-
be@enzolifesciences.com](mailto:info-be@enzolifesciences.com)

France
Phone: +33 472 440 655
[info-
fr@enzolifesciences.com](mailto:info-fr@enzolifesciences.com)

Germany
Phone: +49 7621 5500 526
[info-
de@enzolifesciences.com](mailto:info-de@enzolifesciences.com)

UK & Ireland
Phone (UK customers):
0845 601 1488
Phone: +44 1392 825900
[info-
uk@enzolifesciences.com](mailto:info-uk@enzolifesciences.com)